{"id":7215,"date":"2025-01-29T16:44:31","date_gmt":"2025-01-29T15:44:31","guid":{"rendered":"https:\/\/icoprevencio.cat\/uc\/?page_id=7215"},"modified":"2026-01-27T09:39:23","modified_gmt":"2026-01-27T08:39:23","slug":"eucanscreen","status":"publish","type":"page","link":"https:\/\/icoprevencio.cat\/uc\/eucanscreen\/","title":{"rendered":"EUCanScreen"},"content":{"rendered":"\n
\n

Projectes en curs<\/strong><\/h2><\/div><\/div><\/div><\/div>\n<\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n
\"\"<\/figure><\/div>\n\n\n\n

Acci\u00f3 conjunta per garantir la implementaci\u00f3 sostenible de programes de detecci\u00f3 preco\u00e7 de c\u00e0ncer de mama, coll uter\u00ed i colorectal<\/h3><\/div>

L\u2019objectiu general d\u2019EUCanScreen<\/a> \u00e9s garantir l\u2019aplicaci\u00f3 sostenible d\u2019un cribratge de gran qualitat per als c\u00e0ncers de mama, coll uter\u00ed i colorectal, aix\u00ed com la implementaci\u00f3 dels programes de cribratge recentment recomanats per als c\u00e0ncers de pulm\u00f3, pr\u00f2stata i est\u00f3mac. EUCanScreen contribuir\u00e0 a reduir la c\u00e0rrega del c\u00e0ncer i a promoure l\u2019equitat a tota la UE.

Project ID No.: <\/strong>101162959, Reg. of LU. Nr. ZD2024\/21709
<\/p><\/div><\/div><\/div>\n\n\n\n

\"\"<\/figure>\n\n\n\n
<\/div>\n\n\n
\t\t\t\n\t\t\t\t\t\t\t\t<\/path><\/svg>\n\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t<\/path><\/svg>\n\t\t\t\t\t\t\t<\/span>\n\t\t\tObjectius espec\u00edfics<\/strong><\/strong><\/span><\/div>

S\u2019han establert set objectius espec\u00edfics per a EUCanScreen:

– Garantir la plena implantaci\u00f3 de programes de cribratge per als c\u00e0ncers de mama, coll uter\u00ed i colorectal basats en evid\u00e8ncia, rendibles i amb garantia de qualitat.

– Preparar la implementaci\u00f3 de programes de cribratge per als c\u00e0ncers de pulm\u00f3, pr\u00f2stata i est\u00f3mac basats en evid\u00e8ncia, rendibles i amb garantia de qualitat.

– Assegurar una governan\u00e7a i sostenibilitat adequades dels programes.

– Garantir la recopilaci\u00f3 de dades i el seguiment dels programes de cribratge amb m\u00e9s qualitat, oportunitat i comparabilitat.

– Assegurar la igualtat d\u2019acc\u00e9s dels ciutadans de la UE que compleixin els requisits als programes de cribratge i reduir les desigualtats en la lluita contra el c\u00e0ncer.

– Fomentar el desenvolupament de capacitats en el cribratge del c\u00e0ncer.

– Garantir la col\u00b7laboraci\u00f3 i la coher\u00e8ncia amb projectes relacionats finan\u00e7ats per programes de la UE.
<\/p><\/div><\/div>

\t\t\t\n\t\t\t\t\t\t\t\t<\/path><\/svg>\n\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t<\/path><\/svg>\n\t\t\t\t\t\t\t<\/span>\n\t\t\tM\u00e8todes<\/strong><\/span><\/div>

El pla de treball d\u2019EUCanScreen s\u2019ha basat en els resultats de les principals activitats pr\u00e8vies i actuals de la UE en mat\u00e8ria de cribratge i est\u00e0 estructurat en onze paquets de treball estretament interconnectats.

WP1: Coordinaci\u00f3 del projecte<\/strong>
L\u2019objectiu d\u2019aquest paquet de treball \u00e9s garantir l\u2019\u00e8xit de la implementaci\u00f3 d\u2019EUCanScreen, incloent-hi els requisits d\u2019informaci\u00f3 necessaris.

WP2: Difusi\u00f3<\/strong>
Execuci\u00f3 d\u2019activitats per informar el p\u00fablic objectiu i les parts interessades sobre els resultats d\u2019EUCanScreen, fomentant-ne el suport i l\u2019adopci\u00f3 de les recomanacions del projecte.

WP3: Avaluaci\u00f3<\/strong>
Centrat a documentar aquesta implementaci\u00f3 de la JA mitjan\u00e7ant criteris i dades tra\u00e7ables, i a contribuir a l\u2019assoliment dels objectius de la JA a trav\u00e9s del feedback.

WP4: Sostenibilitat<\/strong>
Assegurar l\u2019aplicaci\u00f3 sostenible dels resultats del projecte als pa\u00efsos participants i millorar la implementaci\u00f3 dels programes de cribratge organitzats i basats en la poblaci\u00f3 als pa\u00efsos de la regi\u00f3 europea on aquests programes encara no s\u2019apliquen o no tenen l\u2019impacte esperat.

WP5: Seguiment<\/strong>
Millorar les normes existents i desenvolupar-ne de noves per a l\u2019intercanvi i la normalitzaci\u00f3 de dades entre pa\u00efsos, amb l\u2019objectiu de millorar el seguiment i la comparaci\u00f3 dels programes de cribratge i facilitar la recerca transfronterera amb dades de cribratge.

WP6: Reducci\u00f3 de desigualtats<\/strong>
Coordinar i donar suport a activitats per reduir les desigualtats en l\u2019acc\u00e9s i la qualitat dels programes de cribratge del c\u00e0ncer de mama, coll uter\u00ed i colorectal, aix\u00ed com dels serveis assistencials a Europa.

WP7: Implementaci\u00f3<\/strong>
Proporcionar eines i recomanacions i arribar a un consens sobre els processos essencials per reduir la bretxa entre el coneixement actual i la pr\u00e0ctica en els programes de cribratge poblacional (c\u00e0ncer de mama, colorectal i de coll uter\u00ed), que ja es duen a terme com a part dels serveis est\u00e0ndard en la majoria de pa\u00efsos de la UE.

WP8: Facilitaci\u00f3<\/strong>
Oferir una visi\u00f3 global de l\u2019estat actual del cribratge del c\u00e0ncer de pulm\u00f3, pr\u00f2stata i est\u00f3mac (\u00e9s a dir, el cribratge recentment recomanat) i informar sobre la seva integraci\u00f3 en la pr\u00e0ctica actual conjuntament amb el cribratge dels c\u00e0ncers de mama, coll uter\u00ed i colorectal.

WP9: Enfocaments basats en el risc<\/strong>
Millorar la comprensi\u00f3 dels conceptes de risc i cribratge basat en el risc, i proporcionar als Estats membres recomanacions per avaluar la possible integraci\u00f3 d\u2019aquests enfocaments en els seus programes de cribratge.

WP10: Modelitzaci\u00f3<\/strong>
Optimitzar i prioritzar els programes de cribratge existents i futurs.

WP11: Desenvolupament de capacitats<\/strong>
Capacitar els l\u00edders actuals i futurs del cribratge del c\u00e0ncer en pa\u00efsos exemplars per implementar amb \u00e8xit o millorar el cribratge poblacional organitzat en els seus respectius pa\u00efsos.
\u00a0<\/p><\/div><\/div>

\t\t\t\n\t\t\t\t\t\t\t\t<\/path><\/svg>\n\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t<\/path><\/svg>\n\t\t\t\t\t\t\t<\/span>\n\t\t\tDuraci\u00f3<\/strong><\/strong><\/span><\/div>

01.06.2024. \u2013 31.05.2028<\/p><\/div><\/div>

\t\t\t\n\t\t\t\t\t\t\t\t<\/path><\/svg>\n\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t<\/path><\/svg>\n\t\t\t\t\t\t\t<\/span>\n\t\t\tFinan\u00e7ament<\/strong><\/strong><\/span><\/div>

38,7M\u20ac (618.706\u20ac per a l\u2019ICO)
<\/p><\/div><\/div>

\t\t\t\n\t\t\t\t\t\t\t\t<\/path><\/svg>\n\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t<\/path><\/svg>\n\t\t\t\t\t\t\t<\/span>\n\t\t\tCoordinaci\u00f3<\/strong><\/strong><\/span><\/div>

University of Latvia
<\/p><\/div><\/div>

\t\t\t\n\t\t\t\t\t\t\t\t<\/path><\/svg>\n\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t<\/path><\/svg>\n\t\t\t\t\t\t\t<\/span>\n\t\t\tSocis del projecte<\/strong><\/strong><\/span><\/div>

Competent Authorities:\u00a0<\/strong>

1. LATVIJAS UNIVERSITATE (LU)
2. GESUNDHEIT OSTERREICH GMBH (AT)
3. SCIENSANO (BE)
4. HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO (HR)
5. Ministry of Health of the Republic of Cyprus (CY)
6. USTAV ZDRAVOTNICKYCH INFORMACI A STATISTIKY CESKE REPUBLIKY (CZ)
7. REGION SYDDANMARK (DK)
8. TERVISE ARENGU INSTITUUT (EE)
9. TERVEYDEN JA HYVINVOINNIN LAITOS (FI)
10. INSTITUT NATIONAL DU CANCER GIP (FR)
11. ROBERT KOCH-INSTITUT (DE)
12. MINISTRY OF HEALTH (EL)
13. ORSZAGOS KORANYI PULMONOLOGIAI INTEZET (HU)
14. HEILSUGAESLA HOFUDBORGARSVAEDISINS (IS)
15. DEPARTMENT OF HEALTH (IE)
16. ISTITUTO PER LO STUDIO E LA PREVENZIONE E LA RETE ONCOLOGICA (IT)
17. LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJA (LT)
18. Ministry for Health and Active Ageing – Government of Malta (MT)
19. INSTITUTIA MEDICO-SANITARA PUBLICA INSTITUTUL ONCOLOGIC (MD)
20. RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU (NL)
21. HELSEDIREKTORATET (NO)
22. NARODOWY INSTYTUT ONKOLOGII IM. MARII SKLODOWSKIEJ-CURIE – PANSTWOWY INSTYTUT BADAWCZY (PL)
23. MINISTERIO DA SAUDE – REPUBLICA PORTUGUESA (PT)
24. INSTITUTUL NATIONAL DE SANATATE PUBLICA (RO)
25. MINISTERSTVO ZDRAVOTNICTVA SLOVENSKEJ REPUBLIKY (SK)
26. ONKOLOSKI INSTITUT LJUBLJANA (SI)
27. INSTITUT CATALA D’ONCOLOGIA (ES)
28. SOCIALSTYRELSEN (SE)
29. STATE INSTITUTION PUBLIC HEALTH CENTER OF THE MINISTRY OF HEALTH OF UKRAINE (UA)

Affiliated Entities:<\/strong>

1. SLIMIBU PROFILAKSES UN KONTROLES CENTRS (LV)\u00a0
2.\u202fRIGAS STRADINA UNIVERSITATE (LV)\u00a0
3.\u202fPAULA STRADINA KLINISKA\u00a0UNIVERSITATES SLIMNICA (LV)\u00a0
4.\u202fUNIVERSITAT FUR WEITERBILDUNG KREMS (AT)\u00a0
5.\u202fUMIT TIROL – PRIVATE UNIVERSITAT FUR GESUNDHEITSWISSENSCHAFTEN UND TECHNOLOGIE GMBH (AT)\u00a0
6.\u202fCENTRUM VOOR KANKEROPSPORING (BE)\u00a0
7.\u202fSTICHTING KANKERREGISTER – FONDATION REGISTRE DU CANCER (BE)\u00a0
8.\u202fCENTRE COMMUNAUTAIRE DE REFERENCE POUR LE DEPISTAGE DES CANCERS (BE)
9.\u202fUNIVERSITAIR ZIEKENHUIS ANTWERPEN (BE)\u00a0
10.\u00a0KLINICKI BOLNICKI CENTAR ZAGREB (HR)\u00a0
11.\u00a0UNIVERSITY OF CYPRUS (CY)\u00a0
12.\u202fTARTU ULIKOOL (EE)\u00a0
13.\u00a0SUOMEN SYOPAYHDISTYS – CANCERFORENINGEN I FINLAND RY – CANCER SOCIETY OF FINLAND CSF (FI)\u00a0
14.\u00a0FEDERATION HOSPITALIERE DE FRANCE (FR)\u00a0
15.\u00a0HOSPICES CIVILS DE LYON (FR)\u00a0
16.\u00a0UNICANCER (FR)\u00a0
17.\u00a0ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (FR)\u00a0
18.\u00a0PLATEFORME DES DONNEES DE SANTE (FR)\u00a0
19. INSTITUT GUSTAVE ROUSSY\u00a0(FR)\u00a0
20.\u202fDEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG (DE)\u00a0
21.\u00a0LEIBNIZ-INSTITUT FUR PRAVENTIONSFORSCHUNG UND EPIDEMIOLOGIE – BIPS GMBH (DE)\u00a0
22.\u00a0DEUTSCHE KREBSGESELLSCHAFT EV (DE)\u00a0
23.\u00a0DIOIKISI 6IS YGEIONOMIKIS PERIFEREIAS PELOPONNISOU IONION NYSON IPEIROU KAI DYTIKIS ELLADAS (EL)\u00a0
24.\u00a0NEMZETI NEPEGESZSEGUGYI ES GYOGYSZERESZETI KOZPONT (HU)\u00a0
25.\u00a0LANDLAEKNIS EMBAETTID (IS)\u00a0
26.\u00a0HEALTH SERVICE EXECUTIVE (IE)\u00a0
27.\u202fROYAL COLLEGE OF SURGEONS IN IRELAND (IE)\u00a0
28.\u00a0ISTITUTO SUPERIORE DI SANITA (IT)\u00a0
29.\u00a0MINISTERO DELLA SALUTE (IT)\u00a0
30.\u00a0AZIENDA UNITA SANITARIA LOCALE DI REGGIO EMILIA (IT)\u00a0
31.\u00a0REGIONE MARCHE (IT)\u00a0
32.\u00a0AZIENDA OSPEDALIERA CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO (IT)\u00a0
33.\u00a0AZIENDA ULSS 4 VENETO ORIENTALE (IT)\u00a0
34.\u202fISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI (IT)\u00a0
35.\u202fUNIVERSITA CATTOLICA DEL SACRO CUORE (IT)\u00a0
36.\u202fPROVINCIA AUTONOMA DI TRENTO (IT)\u00a0
37.\u202fFONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI (IT)\u00a0
38.\u202fREGIONE LOMBARDIA (IT)\u00a0
39.\u202fATS PAVIA (IT)\u00a0
40.\u202fVIESOJI ISTAIGA VILNIAUS UNIVERSITETO LIGONINE SANTAROS KLINIKOS (LT)\u00a0
41.\u202fLIETUVOS SVEITAKOS MOKSLU UNIVERSITETO LIGONINE KAUNO KLINIKOS (LT)\u00a0
42.\u202fERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (NL)\u00a0
43.\u00a0STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (NL)\u00a0
44.\u202fSTICHTING BEVOLKINGSONDERZOEK NEDERLAND (NL)\u00a0
45.\u202fFOLKEHELSEINSTITUTTET (NO)\u00a0
46.\u202fINSTYTUT GRUZLICY I CHOROB PLUC (PL)\u00a0
47.\u202fINSTITUTO PORTUGUES DE ONCOLOGIA DO PORTO FRANCISCO GENTIL, EPE (PT)\u00a0
48.\u202fUNIDADE LOCAL DE SAUDE DE SAO JOAO, E.P.E. (PT)\u00a0
49.\u202fUNIDADE LOCAL DE SA\u00daDE SANTA MARIA (PT)\u00a0
50.\u202fINSTITUTUL CLINIC FUNDENI (RO)\u00a0
51.\u202fINSTITUTUL ONCOLOGIC PROF DR ION CHIRICUTA CLUJ-NAPOCA (RO)
52.\u202fNARODNY ONKOLOGICKY USTAV (SK)\u00a0
53.\u202fNACIONALNI INSTITUT ZA JAVNO ZDRAVJE (SI)\u00a0
54.\u202fASOCIACI\u00d3N INSTITUTO DE INVESTIGACI\u00d3N EN SISTEMAS DE SALUD-BIOSISTEMAK (ES)\u00a0
55.\u202fFUNDACION PARA EL FOMENTO DE LA INVESTIGACION SANITARIA Y BIOMEDICA DE LA COMUNITAT VALENCIANA (ES)\u00a0
56.\u202fINSTITUTO ARAGONES DE CIENCIAS DE LA SALUD (ES)\u00a0
57.\u202fFUNDACION INSTITUTO DE INVESTIGACION MARQUES DE VALDECILLA (ES)\u00a0
58.\u202fFUNDACIO INSTITUT HOSPITAL DEL MAR D INVESTIGACIONS MEDIQUES (ES)\u00a0
59.\u202fSVERIGES KOMMUNER OCH REGIONER (SE)\u00a0
60.\u202fSTATE INSTITUTION VOZIANOV INSTITUTE OF UROLOGY OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE (UA)\u00a0
61.\u202fNATIONAL CANCER INSTITUTE (UA)\u00a0\u00a0

Associated Partners:
<\/strong>
1.\u202fINSTITUT JULES BORDET ASBL (BE)\u00a0\u00a0
2. MINISTERIE VAN VOLKSGEZONDHEID, WELZIJN EN SPORT (NL)\u00a0
3. INSTITUTO TUMORI “GIOVANNI PAOLO II” IRCCS (IT)\u00a0
4. AZIENDA SANITARIA LOCALE TARANTO (IT)\u00a0
5. MSB MEDICAL SCHOOL BERLIN GMBH (DE)\u00a0
6. CENTRUL NATIONAL DE SANATATE MINTALA SI LUPTA ANTODROG (RO)\u00a0
7.\u202fINSTITUTUL REGIONAL DE ONCOLOGIE IASI (RO)\u00a0
8.\u00a0CENTRE BRUXELLOIS DE COORDINATION POUR LE DEPISTAGE ET LA PREVENTION DES CANCERS (BE)\u00a0<\/p><\/div><\/div>

\t\t\t\n\t\t\t\t\t\t\t\t<\/path><\/svg>\n\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t<\/path><\/svg>\n\t\t\t\t\t\t\t<\/span>\n\t\t\tEquip d\u2019Investigaci\u00f3 UCC:
<\/strong><\/strong><\/span><\/div>

Gemma Binefa
Nuria Vives
Montse Garc\u00eda
Noemie Travier
Berta Casas
Jon Aritz Panera
Marcos Castej\u00f3n<\/p><\/div><\/div>

\t\t\t\n\t\t\t\t\t\t\t\t<\/path><\/svg>\n\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t<\/path><\/svg>\n\t\t\t\t\t\t\t<\/span>\n\t\t\tPublicacions cient\u00edfiques<\/strong><\/strong><\/span><\/div>

Encara no hi han publicacions\u2026<\/p><\/div><\/div>

\t\t\t\n\t\t\t\t\t\t\t\t<\/path><\/svg>\n\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t<\/path><\/svg>\n\t\t\t\t\t\t\t<\/span>\n\t\t\tInformaci\u00f3 de contacte<\/strong><\/strong><\/span><\/div>

Project Coordinator<\/strong>: University of Latvia (Latvijas Universit\u0101te)
Email<\/strong>: screening@lu.lv<\/p><\/div><\/div><\/div>\n\n\n

<\/div>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":28,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_vp_format_video_url":"","_vp_image_focal_point":[],"footnotes":""},"class_list":["post-7215","page","type-page","status-publish","hentry"],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"vp_sm":false,"vp_md":false,"vp_lg":false,"vp_xl":false,"vp_sm_popup":false,"vp_md_popup":false,"vp_xl_popup":false},"uagb_author_info":{"display_name":"clara","author_link":"https:\/\/icoprevencio.cat\/uc\/author\/clara\/"},"uagb_comment_info":0,"uagb_excerpt":null,"_links":{"self":[{"href":"https:\/\/icoprevencio.cat\/uc\/wp-json\/wp\/v2\/pages\/7215","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/icoprevencio.cat\/uc\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/icoprevencio.cat\/uc\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/icoprevencio.cat\/uc\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/icoprevencio.cat\/uc\/wp-json\/wp\/v2\/comments?post=7215"}],"version-history":[{"count":8,"href":"https:\/\/icoprevencio.cat\/uc\/wp-json\/wp\/v2\/pages\/7215\/revisions"}],"predecessor-version":[{"id":8220,"href":"https:\/\/icoprevencio.cat\/uc\/wp-json\/wp\/v2\/pages\/7215\/revisions\/8220"}],"wp:attachment":[{"href":"https:\/\/icoprevencio.cat\/uc\/wp-json\/wp\/v2\/media?parent=7215"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}